Regulatory pathway
Is Compounded Tirzepatide Still Legal in 2026?
Yes. Compounded tirzepatide remains legal in 2026 for individual patients with documented medical necessity, dispensed by a state-licensed 503A pharmacy against a patient-specific prescription. Mass compounding by 503B outsourcing facilities ended on March 19, 2025. The 503A patient-specific exception did not.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 6, 2026.What changed in March 2025
For most of 2023 and 2024, brand-name tirzepatide (Mounjaro and Zepbound, both manufactured by Eli Lilly) was on the FDA drug shortage list. While a drug is on that list, FDA exercises enforcement discretion that allows both 503A pharmacies and 503B outsourcing facilities to compound the molecule beyond the usual patient-specific limits. That discretion was the basis for the rapid expansion of compounded tirzepatide programs.
FDA officially resolved the tirzepatide shortage in late 2024 and gave compounders a wind-down period. The deadlines were:
- February 18, 2025 — end of FDA enforcement discretion for 503A pharmacies compounding tirzepatide on a shortage basis.
- March 19, 2025 — end of FDA enforcement discretion for 503B outsourcing facilities compounding tirzepatide on a shortage basis.
What ended is the workaround that let pharmacies mass-compound the drug for clinic stock during the shortage. What did not end is the underlying statutory authority for compounding patient-specific prescriptions.
The 503A patient-specific exception (still legal)
Section 503A of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. § 353a) authorizes state-licensed pharmacies and physicians to compound a drug for an identified individual patient. The compound must be prepared based on a patient-specific prescription, must be made for an identified patient with documented medical need, must not be made for resale, and must not be made in bulk anticipating prescriptions that have not been written.
This pathway has existed for decades. It is the same legal authority that lets a pharmacy compound a custom-strength testosterone cream, a sterile injection in a strength not commercially available, or a flavored pediatric suspension when a child cannot swallow a commercial tablet. It applies to compounded tirzepatide the same way it applies to any other compounded medication.
The 503A pathway does not depend on FDA enforcement discretion and was not affected by the February or March 2025 deadlines. It is independently authorized by statute.
When compounded tirzepatide is clinically appropriate
A licensed prescriber documents medical necessity in the chart for every patient. Common indications PeptideRx providers see:
- Documented intolerance to brand-name tirzepatide due to nausea, injection-site reactions, or sensitivity to brand excipients.
- Need for a dose strength that is not commercially available, including ultra-slow titration steps for patients sensitive to GI side effects.
- Need for the combined formulation with B12 (cyanocobalamin) or glycine, which can mitigate nausea and injection-site discomfort.
- Patient is unable to access brand-name tirzepatide due to cost, formulary restriction, or local supply.
Each of these is a documented clinical reason that satisfies the medical-need requirement under Section 503A.
How PeptideRx operates within this pathway
- Patient-specific prescriptions. Every order is preceded by a telehealth consultation with a licensed nurse practitioner or physician assistant employed by PeptideRx. The prescription is written for one identified patient.
- Documented medical necessity. Every chart includes the clinical rationale for the compounded formulation. We do not write generic shortage-based justifications.
- Dispensed by a 503A pharmacy. Optimal Balance Pharmacy is licensed in Texas as a 503A sterile compounding pharmacy. They compound only against patient-specific prescriptions we transmit. They do not bulk-compound, do not stock office inventory, and do not resell.
- USP <797> sterile compounding standards. Every sterile batch is endotoxin and sterility tested. Beyond Use Dates are assigned per USP <797> and printed on every vial.
- Two-fee structure. You pay PeptideRx a flat $39 visit fee for the medical visit. You pay Optimal Balance Pharmacy directly for the medication at wholesale. We do not mark up the medication.
Brand-name vs compounded tirzepatide
| Dimension | Brand (Mounjaro / Zepbound) | Compounded via PeptideRx |
|---|---|---|
| Active ingredient | Tirzepatide (Eli Lilly) | Tirzepatide compounded by 503A pharmacy |
| FDA-approved drug product | Yes (Mounjaro, Zepbound) | No. Not FDA-approved. Legal under 503A patient-specific exception. |
| Cash price (typical) | $1,000+/month at retail; $299–$449 through LillyDirect | $45–$675/month depending on dose strength |
| Dose strengths available | 6 fixed doses (2.5, 5, 7.5, 10, 12.5, 15 mg) | 10 vial sizes from 12mg to 180mg, plus dose flexibility within each |
| Carrier formulation | Brand-name excipients only | B12 or B6+glycine carrier options |
| Prescriber | Any licensed prescriber | Licensed prescriber writing a patient-specific Rx for documented medical need |
| Dispensing pharmacy | Any retail pharmacy (or LillyDirect) | 503A licensed compounding pharmacy (PeptideRx uses Optimal Balance, TX) |
Brand-name pricing reflects publicly listed cash prices and LillyDirect offering as of May 2026; check current pricing with your pharmacy. Compounded pricing is the OBP wholesale rate Marcus negotiated; see the Tirzepatide/B12 page for the full per-dose ladder.
Ready to start a documented protocol?
PeptideRx providers screen every patient for the documented medical-need criteria above before writing a prescription. The visit fee is $39 and the pharmacy bills you directly at wholesale.
Common questions about compounded tirzepatide legality
- Is this the same as the gray-market peptides on bodybuilding sites?
- No. Gray-market peptides labeled "research only" are not prescribed, not patient-specific, and are not made by a licensed pharmacy. Compounded tirzepatide from PeptideRx is prescribed by a licensed nurse practitioner or physician assistant after a documented telehealth visit and dispensed by Optimal Balance Pharmacy, a 503A-licensed compounding pharmacy in Texas.
- Will my insurance cover compounded tirzepatide?
- Generally no. Compounded medications are typically not covered by commercial insurance because they are not FDA-approved drug products. Patients pay PeptideRx a flat $39 medical visit fee and pay Optimal Balance Pharmacy directly for the medication at wholesale.
- Can a 503A pharmacy ship across state lines?
- Yes, when the prescriber and the patient are licensed and located in compatible states. PeptideRx providers hold telehealth licenses in 33 states and Optimal Balance Pharmacy ships to those states by FedEx 2-day. The full state list is on our About page.
- What documentation does my chart need for 503A compounding?
- A patient-specific prescription written by a licensed provider after a telehealth consultation, plus chart notes documenting the medical reason the compounded formulation is appropriate for that patient. PeptideRx providers complete this documentation as part of every intake review.
- What if my state restricts compounded GLP-1 medications?
- A small number of states have additional restrictions on compounded GLP-1 medications. PeptideRx providers verify state-specific eligibility during the intake screening. If your state restricts the medication you requested, your provider will tell you before charging the visit fee.
- What happens if FDA policy changes again?
- PeptideRx operates strictly under the 503A patient-specific exception, which is statutory under Section 503A of the Federal Food, Drug, and Cosmetic Act. That pathway does not depend on FDA enforcement discretion or shortage status. If broader policy changes affect compounded tirzepatide, we will publish an update on this page within 24 hours.